22 insiders reported 61 Form 4 transactions for CRESCENT BIOPHARMA, INC. (CBIO) over the past 18 months (most recent 2026-07-20). Recent activity: Harwin Peter Evan (Director) Buy 853,450 shares, Fairmount Healthcare Fund II L.P. (Director) Buy 853,450 shares, Fairmount Funds Management LLC (Director) Buy 853,450 shares, Kiselak Tomas (Director) Buy 853,450 shares, Brumm Joshua T (Chief Executive Officer) Sell 42,305 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-20 | Harwin Peter Evan | Director | Buy | 853,450 | $12.4M |
| 2026-07-20 | Fairmount Healthcare Fund II L.P. | Director | Buy | 853,450 | $12.4M |
| 2026-07-20 | Fairmount Funds Management LLC | Director | Buy | 853,450 | $12.4M |
| 2026-07-20 | Kiselak Tomas | Director | Buy | 853,450 | $12.4M |
| 2026-06-23 | Brumm Joshua T | Chief Executive Officer | Sell | 42,305 | $761,067 |
| 2026-06-23 | Lynch Ryan | See Remarks | Sell | 465 | $8,365 |
| 2026-06-23 | Scalzo Richard William | Chief Financial Officer | Sell | 1,112 | $20,005 |
| 2026-06-23 | McNeill Jonathan | President and COO | Sell | 20,549 | $369,677 |
| 2026-06-23 | Im Ellie Eunkyung | Chief Medical Officer | Sell | 1,219 | $21,930 |
| 2026-06-23 | Bispham Barbara Harlin | See Remarks | Sell | 1,218 | $21,912 |
| 2026-06-23 | Pinkas Jan | Chief Scientific Officer | Sell | 1,288 | $23,171 |
| 2025-12-17 | Doughty Christopher Grant | Chief Business Officer | Buy | 8,000 | $0 |
| 2025-12-17 | Doughty Christopher Grant | Chief Business Officer | Buy | 14,714 | $0 |
| 2025-12-17 | Brumm Joshua T | Chief Executive Officer | Buy | 45,117 | $0 |
| 2025-12-17 | Brumm Joshua T | Chief Executive Officer | Buy | 10,000 | $0 |
| 2025-12-17 | Bispham Barbara Harlin | See Remarks | Buy | 12,422 | $0 |
| 2025-12-17 | Bispham Barbara Harlin | See Remarks | Buy | 6,000 | $0 |
| 2025-12-17 | Im Ellie Eunkyung | Chief Medical Officer | Buy | 16,298 | $0 |
| 2025-12-17 | Im Ellie Eunkyung | Chief Medical Officer | Buy | 5,000 | $0 |
| 2025-12-17 | Pinkas Jan | Chief Scientific Officer | Buy | 17,507 | $0 |
| 2025-12-17 | Pinkas Jan | Chief Scientific Officer | Buy | 5,000 | $0 |
| 2025-12-17 | Scalzo Richard William | Chief Financial Officer | Buy | 14,422 | $0 |
| 2025-12-17 | Scalzo Richard William | Chief Financial Officer | Buy | 5,000 | $0 |
| 2025-12-17 | Lynch Ryan | See Remarks | Buy | 8,378 | $0 |
| 2025-12-17 | Lynch Ryan | See Remarks | Buy | 4,000 | $0 |
Source: SEC Form 4 filings · as of 2026-07-20